Henrik Schmidt

Ekstern lektor, Klinisk lektor

Profile photoHenrik Schmidt
Klinisk lektor, overlæge

Institut for Klinisk Medicin - Kræftafdelingen

Postaddresse:
Palle Juul-Jensens Boulevard 99
8200 Aarhus N
Danmark

E-mail: henrschm@rm.dk
Telefon: +4578461682

Fødselsår

1964

Uddannelser

2007D.M.Sc in Medicine. Health, Aarhus Universitet, Danmark
2006Specialist in Medical Oncology and Radiotherapy, National Board of Health, København, Denmark
2002Tilladelse til at praktisere uafhængigt som læge: Health, København, Danmark
1992Læge authorisation, Health, School of Medicine, Aarhus Universitet, Danmark

Akademiske grader

2007Medicinsk doktorgrad

Forskningsområder

Immuneterapi
Inflammations celler og melanom
Biomarkører ved melanom

Nuværende ansættelse

2011-Klinisk lektor, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
2008-Overlæge, Leder af Klinisk Forskningsenhed, Onkologisk afdeling, Aarhus Universitetshospital, Danmark

Tidligere ansættelser

2008Overlæge, Leder af Klinisk Forsningsenhed, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
2006-2008Afdelingslæge, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
2005-20061. Reservelæge, Onkologisk afdeling, Aalborg
2002-2005Reservelæge, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
1997-2002Forskningsstipendiat, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
1995-1996Reservelæge, Onkologisk afdeling Aarhus Universitetshospital, Danmark
1997Forskningsstipendiat, Institute of Medical Microbiology and Immonology, Aarhus Universitetshospital, Danmark

Publikationer og repræsentationer

Publikationer: 36, Peer-reviewed artikler: 36, H-index: 16, Citations: 614, Præsentationer ved videnskabelige møder (oral): 25

Udvalgs- og bestyrelsesposter

Medlem af bestyrelsen for Dansk Melanom Gruppe

Organisering af kliniske forsøg

PRINCIPAL INVESTIGATOR:
A phase 1, Open label, dose escalation, safety and tolerability study of subcutaneous administration of recombinant human interleukin-21 in patients with stage IV melanoma or stage IV renal cell carcinoma (GCP).
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk stage III melanoma: A randomized, double-blind phase 3 trial of the EORTC melanoma group (GCP).
An Open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma (GCP).
A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma (GCP).
A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.
A phase III (COMBI-AD) randomized double blind study of dabrafenib in COMBInation with trametinib versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-
positive melanoma after surgical resection.(GCP).

NATIONAL INVESTIGATOR:
An exploratory study to determine potential predictive markers of response and/or toxicity in patients with unresectable stage III or IV malignant melanoma randomized and treated with Ipilimumab (MDX-010) at two dose levels (GCP).
A Multicenter, Open-Label, Phase II study of Ipilimumab (MDX-010) extended treatment monotherapy or follow-up for patients previously enrolled in Ipilimumab (MDX-010) protocols (GCP).
A Randomized, multi dose, open-label, phase II study of BMS-663513 as a second-line monotherapy in subjects with previously treated unresectable stage III or stage IV melanoma (GCP).
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma (GCP).
A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects with Previously Untreated Unresectable or Metastatic Melanoma (GCP).
A phase III, randomized, double-blind study of nivolumab monotherapy or nivolumab combined with ipilimumab versus ipilimumab monotherapy in subjects with previously untreated unresectable or metastatic melanoma.

CO-INVESTIGATOR:
Phase III multinational trial, adjuvant Interferon trial, Nordic Melanoma Group.
A phase II trial of Interleukin 2, Interferon and Histamine, Danish Melanoma Group.
A phase I trial in metastatic melanoma: Adoptive transfer of allogeneic, cytotoxic T-lymphocytes equipped with a MART-1 T-cell receptor restricted by HLA-A2 (GCP), Danish Melanoma Group.
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma (GCP), Danish Melanoma Group.

Vejledning

Vejleder for 7 ph.d.-studerende, Health, Aarhus Universitet, Danmark
Vejleder for 2 ph.d.-studerende, Det Sundhedsvidenskabelige Fakultet, Syddansk Universitet, Odense, Danmark
Vejleder for 1 Cand. Scient. San student, Health, Aarhus Universitet, Danmark
Vejleder for 2 forskningsårsstuderende, Health, Aarhus Universitet, Danmark

Bedømmelser

Ph.d. afhandlinger:
3 studenter ved Health, Det Sundhedsvidenskabelige Fakultet, Købenahvns Universitet, Danmark

Formand for ph.d. bedømmelsesudvalg:
2 studenter ved Health, Aarhus Universitet, Danmark

Censor ved forskningsårsstuderendes eksamen:
2 studenter ved Health, Aarhus Universitet, Danmark

Awards and grants

William Nielsen Fondens hæderspris (2013)
Hede Nielsen fondens hæderspris, sammen med Lars Bastholt og Inge Marie Svane (2010)
Bernhard Rasmussen og frue Meta Rasmussens mindelegat (2008)
ASCO merit Award, Florida, USA (2005)

Større forskningsbevillinger

Kræftens Bekæmpelse:
Characterisation of subtypes of innate immune cells in ulcerated melanomas (2012-2015)

Organisering af møder

Medlem af the organizing and scientific committee of the Nordic Melanoma Group møde (2013)
Member of the organizing committee of the Clinical Research Unit møde, Aarhus (2013)
Medlem af the organizing and scientific committee of the euMEET, Aarhus (2012)
Medlem af the organizing committee of the Clinical Research Unit møde, Aarhus (2011)
Medlem af the organizing committee of the Clinical Research Unit møde, Aarhus (2010)
Medlem af the organizing committee of the Clinical Research Unit møde, Aarhus (2009)
Medlem af the organizing and scientific committee of the Nordic Melanoma Group møde (2008)

Involvering i videnskabelige tidsskrifter

Manuscript anmelder for blandt andre:
Clinical Cancer Research
Journal of Investigative Dermatology
Clinical Chemistry
European Journal of Cancer
British Journal of Dermatology
Journal of Translational Medicine
Melanoma Research

Medlemsskaber

Danish Melanoma Group, board member (2012-)
American Society of Clinical Oncology (2008-)
European Organization for Research and Treatment of Cancer (EORTC) (2007-)
Nordic Melanoma Group (2007-)
Danish Society of Clinical Oncology
Danish Association for Cancer Research

Publikationer

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Rutkowski, P., Hassel, J. C., McNeil, C. M., Kalinka, E. A., Lebbé, C., Charles, J., Hernberg, M. M., Savage, K. J., Chiarion-Sileni, V., Mihalcioiu, C., Mauch, C., Arance, A., Cognetti, F., Ny, L., Schmidt, H., Schadendorf, D., Gogas, H., Zoco, J., Re, S., Ascierto, P. A. & Atkinson, V., nov. 2020, I : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 33, s. 3937-3946 10 s.

Granzyme B degraded type IV collagen products in serum identify melanoma patients responding to immune checkpoint blockade

Jensen, C., Sinkeviciute, D., Madsen, D. H., Önnerfjord, P., Hansen, M., Schmidt, H., Karsdal, M. A., Svane, I. M. & Willumsen, N., okt. 2020, I : Cancers. 12, 10, 15 s., 2786.

Improved progression-free long-term survival of a nation-wide patient population with metastatic melanoma

Soerensen, A. V., Ellebaek, E., Bastholt, L., Schmidt, H., Donia, M. & Svane, I. M., sep. 2020, I : Cancers. 12, 9, 11 s., 2591.

Severe steroid refractory gastritis induced by Nivolumab: A case report

Vindum, H. H., Agnholt, J. S., Nielsen, A. W. M., Nielsen, M. B. & Schmidt, H., apr. 2020, I : World Journal of Gastroenterology. 26, 16, s. 1971-1978 8 s.

Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines

Christensen, J. N., Schmidt, H., Steiniche, T. & Madsen, M., 2020, I : Melanoma Research. 30, 1, s. 26-38 13 s.

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., van Schoiack, A., Lövgren, K., Warren, S., Jirström, K., Olsson, H., Pietras, K., Ingvar, C., Isaksson, K., Schadendorf, D., Schmidt, H., Bastholt, L., Carneiro, A., Wargo, J. A., Svane, I. M. & Jönsson, G., 2020, I : Nature. 577, 7791, s. 561-565 5 s.

The impact of patient involvement in research: a case study of the planning, conduct and dissemination of a clinical, controlled trial

Skovlund, P. C., Nielsen, B. K., Thaysen, H. V., Schmidt, H., Finset, A., Ahm Hansen, K. & Lomborg, K., 2020, I : Research Involvement and Engagement. 6, 16 s., 43.

A case report: metastasis of melanoma to the heart in an era of immunotherapy

Poulsen, C. B., Weile, K. S., Schmidt, H. & Poulsen, S. H., dec. 2019, I : European Heart Journal: Case Reports. 3, 4, s. 1-7 7 s.

Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

Ismail, H., Helby, J., Hölmich, L. R., Chakera, A. H., Bastholt, L., Klyver, H., Sjøgren, P., Schmidt, H., Schöllhammer, L., Johansen, J. S., Nordestgaard, B. G. & Bojesen, S. E., nov. 2019, I : European Journal of Cancer. 121, s. 74-84 11 s.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., sep. 2019, I : European Journal of Cancer. 119, s. 1-10 10 s.

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Bastholt, L., Schmidt, H., Bjerregaard, J. K., Herrstedt, J. & Svane, I. M., sep. 2019, I : European Journal of Cancer. 119, s. 122-131 10 s.

Immunterapi til patienter med malignt melanom og hjernemetastaser

Simonsen, L. T., Schmidt, A. M. S., Øllegaard, T. H., Svane, I. M., Bastholt, L., Luczak, A. A. & Schmidt, H., jun. 2019, I : Ugeskrift for Læger . 181, 24, V01190057.

Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status

Dabrosin, N., Sloth Juul, K., Bæhr Georgsen, J., Andrup, S., Schmidt, H., Steiniche, T., Heide Øllegaard, T. & Bønnelykke Behrndtz, L., feb. 2019, I : Melanoma Research. 29, 1, s. 30-37 8 s.

The real-world impact of modern treatments on the survival of patients with metastatic melanoma

Donia, M., Ellebaek, E., Øllegaard, T. H., Duval, L., Aaby, J. B., Hoejberg, L., Køhler, U. H., Schmidt, H., Bastholt, L. & Svane, I. M., feb. 2019, I : European Journal of Cancer. 108, s. 25-32 8 s.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Hoejberg, L., Schmidt, H., Van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G. V., Atkinson, V., Blank, C. U. & Neyns, B., 2019, I : Annals of Oncology. 30, 7, s. 1154-1161 8 s.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort

Bastholt, L., Svane, I. M., Bjerregaard, J. K., Herrstedt, J., Hróbjartsson, A. & Schmidt, H., 2019, I : European Journal of Cancer. 115, s. 61-67 7 s.

Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma

Bol, K. F., Ellebaek, E., Hoejberg, L., Bagger, M. M., Larsen, M. S., Klausen, T. W., Køhler, U. H., Schmidt, H., Bastholt, L., Kiilgaard, J. F., Donia, M. & Svane, I. M., 2019, I : Cancers. 11, 10, 11 s., 1489.

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Jensen, C., Madsen, D. H., Hansen, M., Schmidt, H., Svane, I. M., Karsdal, M. A. & Willumsen, N., 19 dec. 2018, I : Journal for immunotherapy of cancer. 6, 10 s.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

Long, G. V., Weber, J. S., Larkin, J., Atkinson, V., Grob, J-J., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., Schmidt, H., Briscoe, K., Baurain, J-F., Hodi, F. S. & Wolchok, J. D., 1 nov. 2017, I : JAMA Oncology. 3, 11, s. 1511-1519 9 s.

Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

Kondrup, M., Raunkilde, L., Svane, I. M., Schmidt, H. & Bastholt, L., 2 okt. 2017, I : Ugeskrift for Laeger. 179, 40, s. 2-6 5 s.

Quantification of microRNA-21 and microRNA-125b in melanoma tissue

Wandler, A., Riber-Hansen, R., Hager, H., Hamilton-Dutoit, S. J., Schmidt, H., Nielsen, B. S., Stougaard, M. & Steiniche, T., okt. 2017, I : Melanoma Research. 27, 5, s. 417-428 12 s.

Predictors of responses to immune checkpoint blockade in advanced melanoma

Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternes, N., Jegou, S., Woods, D. M., Sodre, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., Kuchroo, V. K., Weide, B., Aubin, F., Borg, C., Dalle, S., Beatrix, O., Ayyoub, M., Balme, B., Tomasic, G., Di Giacomo, A. M., Maio, M., Schadendorf, D., Melero, I., Dreno, B., Khammari, A., Dummer, R., Levesque, M., Koguchi, Y., Fong, L., Lotem, M., Baniyash, M., Schmidt, H., Svane, I. M., Kroemer, G., Marabelle, A., Michiels, S., Cavalcanti, A., Smyth, M. J., Weber, S., Eggermont, A. M. & Zitvogel, L., 19 sep. 2017, I : Nature Communications. 8, 13 s., 592.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R., Idorn, M., Munir Ahmad, S., Ellebæk, E., Mueller, A., Fagone, P., Nicoletti, F., Libra, M., Lauss, M., Hadrup, S. R., Schmidt, H., Andersen, M. H., Thor Straten, P., Nilsson, J. A., Schumacher, T. N., Seliger, B., Jönsson, G. & Svane, I. M., 1 sep. 2017, I : Cancer Research. 77, 17, s. 4562-4566 5 s.

Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration

Bønnelykke-Behrndtz, M. L., Steiniche, T., Nørgaard, P., Danielsen, A. V., Damsgaard, T. E., Christensen, I. J., Bastholt, L., Møller, H. J. & Schmidt, H., sep. 2017, I : American Journal of Dermatopathology. 39, 9, s. 672-678 7 s.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M. & Levy, R., 15 apr. 2017, I : Clinical Cancer Research. 23, 8, s. 1929-1936 8 s.

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

Coens, C., Suciu, S., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Bottomley, A., Kotapati, S., de Pril, V., Testori, A. & Eggermont, A. M. M., mar. 2017, I : Lancet Oncology. 18, 3, s. 393-403 11 s.

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H. & Svane, I. M., mar. 2017, I : European journal of cancer (Oxford, England : 1990). 74, s. 89-95 7 s.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

D'Angelo, S. P., Larkin, J., Sosman, J. A., Lebbé, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J. C., Hodi, F. S., Lorigan, P., Savage, K. J., Miller, W. H., Mohr, P., Marquez-Rodas, I., Charles, J., Kaatz, M., Sznol, M., Weber, J. S., Shoushtari, A. N., Ruisi, M., Jiang, J. & Wolchok, J. D., 10 jan. 2017, I : Journal of Clinical Oncology. 35, 2, s. 226-235 10 s.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J. C., Hodi, F. S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S. & Testori, A., 10 nov. 2016, I : The New England Journal of Medicine. 375, 19, s. 1845-1855 11 s.

Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedre prognosen

Boyles, T. B., Svane, I. M., Bastholt, L. & Schmidt, H., 29 aug. 2016, I : Ugeskrift for Laeger. 178, 23, 4 s., V02160126 .

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Fløe, L. E., Svane, I. M., Bastholt, L. & Schmidt, H., 15 aug. 2016, I : Ugeskrift for Laeger. 178, 21, 4 s., V01160070 .

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

Krogh, M., Christensen, I., Bouwhuis, M., Johansen, J. S., Nørgaard, P., Schmidt, H., Hansson, J., Suciu, S., Eggermont, A. M. M., Bastholt, L. & Nordic Melanoma Group and EORTC Melanoma Group, aug. 2016, I : Melanoma Research. 26, 4, s. 367-76 10 s.

Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma

Nielsen, P. S., Riber-Hansen, R., Schmidt, H. & Steiniche, T., 9 apr. 2016, I : Diagnostic Pathology. 11, s. 35

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

Bjoern, J., Juul Nitschke, N., Zeeberg Iversen, T., Schmidt, H., Fode, K. & Svane, I. M., apr. 2016, I : OncoImmunology. 5, 4, 10 s., e1100788.

Consumption of the Epidermis: A Suggested Precursor of Ulceration Associated With Increased Proliferation of Melanoma Cells

Bønnelykke-Behrndtz, M. L., Schmidt, H., Damsgaard, T. E., Christensen, I. J., Bastholt, L., Møller, H. J., Nørgaard, P. & Steiniche, T., nov. 2015, I : American Journal of Dermatopathology. 37, 11, s. 841-5 5 s.

The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer

Antonio, N., Bønnelykke-Behrndtz, M. L., Ward, L. C., Collin, J., Christensen, I. J., Steiniche, T., Schmidt, H., Feng, Y. & Martin, P., 2 sep. 2015, I : E M B O Journal. 34, 17, s. 2219-36 18 s.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Konto, C., Hoos, A., de Pril, V., Gurunath, R. K., de Schaetzen, G., Suciu, S. & Testori, A., maj 2015, I : Lancet Oncology. 16, 5, s. 522-30 9 s.

MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin

Bønnelykke-Behrndtz, M. L., Steiniche, T., Damsgaard, T. E., Georgsen, J. B., Danielsen, A., Bastholt, L., Møller, H. J., Nørgaard, P. H. & Schmidt, H., apr. 2015, I : Melanoma Research. 25, 2, s. 113-8 6 s.

Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma

Køstner, A. H., Ellegaard, M-B. B., Christensen, I. J., Bastholt, L. & Schmidt, H., mar. 2015, I : Cancer Immunology, Immunotherapy. 64, 3, s. 349-55 7 s.

Ipilimumab til behandling af metastaserende melanoma

Ghasemi, H., Schmidt, H. & Stolle, L. B., 26 jan. 2015, I : Ugeskrift for Laeger. 177, 2A, s. 108-9 2 s.

Nivolumab in previously untreated melanoma without BRAF mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V. & Ascierto, P. A., 22 jan. 2015, I : The New England Journal of Medicine. 372, 4, s. 320-30 11 s.

Prognostic stratification of ulcerated melanoma: not only the extent matters

Bønnelykke-Behrndtz, M. L., Schmidt, H., Christensen, I. J., Damsgaard, T. E., Møller, H. J., Bastholt, L., Nørgaard, P. H. & Steiniche, T., dec. 2014, I : American Journal of Clinical Pathology. 142, 6, s. 845-56 12 s.

Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker

Lade-Keller, J., Riber-Hansen, R., Guldberg, P., Schmidt, H., Hamilton-Dutoit, S. J. & Steiniche, T., jun. 2014, I : Journal of Clinical Pathology. 67, 6, s. 520-8 9 s.

Ipilimumab til behandling af metastaserende melanom

Ghasemi, H., Schmidt, H. & Stolle, L. B., 5 aug. 2013, I : Ugeskrift for Laeger.

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma

Nielsen, P. S., Riber-Hansen, R., Jensen, T. Ø., Schmidt, H. & Steiniche, T., 1 mar. 2013, I : Modern Pathology. 26, 3, s. 404-413 10 s.

Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma

Zukauskaite, R., Schmidt, H., Asmussen, J. T., Hansen, O. & Bastholt, L., 2013, I : Melanoma Research. 23, 1, s. 21-6 6 s.

Regression in cancer following fever and acute infection

Køstner, A. H., Johansen, R. F., Schmidt, H. & Mølle, I., 2013, I : Acta Oncologica. 52, 2, s. 455-7 3 s.

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

Jensen, T. Ø., Schmidt, H., Møller, H. J., Donskov, F., Høyer, M., Sjoegren, P., Christensen, I. J. & Steiniche, T., 1 maj 2012, I : Cancer. 118, 9, s. 2476-2485

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

Shahabi, V., Whitney, G., Hamid, O., Schmidt, H., Chasalow, S. D., Alaparthy, S. & Jackson, J. R., 2012, I : Cancer Immunology, Immunotherapy. 61, 5, s. 733-7 5 s.

CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis

Weischer, M., Heerfordt, I. M., Bojesen, S. E., Eigentler, T., Garbe, C., Röcken, M., Hölmich, L. R., Schmidt, H., Klyver, H., Bastholt, L. & Nordestgaard, B. G., 2012, I : Journal of Investigative Dermatology. 132, 2, s. 299-303 5 s.

Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004-2009

Frøslev, T., Grann, A. F., Olsen, M., Olesen, A. B., Schmidt, H., Friis, S. & Søgaard, M., 2012, I : Clinical Epidemiology. 4, S2, s. 5-10 6 s.

Interleukin-6 and melanoma

Hoejberg, L., Bastholt, L. & Schmidt, H., 2012, I : Melanoma Research. 22, 5, s. 327-33 7 s.

Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

Hoejberg, L., Bastholt, L., Johansen, J. S., Christensen, I. J., Gehl, J. & Schmidt, H., 2012, I : Melanoma Research. 22, 4, s. 287-93 7 s.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., Chasalow, S. D. & Berman, D., 2011, I : Journal of Translational Medicine. 9, s. 204

An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., Jackson, J. R. & Shahabi, V., 2011, I : Cancer Immunology, Immunotherapy.

Tumor and inflammation markers in melanoma using tissue microarrays: a validation study

Riber-Hansen, R., Schmidt, H., Hamilton-Dutoit, S. J., Steiniche, T. & Jensen, T. Ø., 2011, I : Melanoma Research Today. 21, 6, s. 509-15 7 s.

Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial

Schmidt, H., Brown, J., Mouritzen, U., Selby, P., Fode, K., Svane, I. M., Cook, G. P., Mollerup, D. H. & Geertsen, P. F., 1 nov. 2010, I : Clinical Cancer Research. 16, 21, s. 5312-9 8 s.

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma

Jensen, T. O., Schmidt, H., Møller, H. J., Høyer, M., Maniecki, M. B., Sjøgren, P., Christensen, I. J. & Steiniche, T., 10 jul. 2009, I : Journal of Clinical Oncology. 27, 20, s. 3330-3337 8 s.

Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709)

Køllgaard, T., Duval, L., Schmidt, H., Kaltoft, K., Seremet, T., Andersen, M. H., von der Maase, H., Straten, P. T. & Hadrup, S. R., 2009, I : Cytotherapy. 11, 5, s. 631-41 10 s.

Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma

Jensen, T. Ø., Schmidt, H., Møller, H. J., Høyer, M., Maniecki, M. B., Sjoegren, P., Christensen, I. J. & Steiniche, T., 2009, I : Journal of Clinical Oncology. 27, 20, s. 3330-3337 7 s.

Participation in an unstructured supportive group as experienced by patients with advanced cancer disease: A preliminary study

Pedersen, A. F., Schmidt, H., Trautner, T. & Jensen, A. B., 2009, I : Acta Oncologica. 48, 7, s. 1074-7 4 s.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt, H., Suciu, S., Punt, C. J. A., Gore, M., Kruit, W., Patel, P., Lienard, D., von der Maase, H., Eggermont, A. M. M. & Keilholz, U., 2007, I : Journal of Clinical Oncology. 25, 12, s. 1562-9 7 s.

The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.

Hernberg, M., Mattila, P. S., Rissanen, M., Hansson, J., Aamdal, S., Bastholt, L., von der Maase, H., Schmidt, H., Stierner, U. & Tarkkanen, J., 2007, I : Journal of Immunotherapy. 30, 7, s. 773-9 6 s.

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma

Duval, L., Schmidt, H., Kaltoft, K., Fode, K., Jensen, J. J., Sørensen, S. M., Nishimura, M. I. & Maase, H. V. D., 2006, I : Clinical Cancer Research. 12, 4, s. 1229-1236

Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma

Schmidt, H., Sørensen, B. S., Sjøgren, P., Christensen, I. J., Fode, K., Larsen, J., Nexø, E. & Maase, H. V. D., 2006, I : J. Invest. Dermatol.. 126, s. 849-854 6 s.

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma

Schmidt, H., Johansen, J. S., Gehl, J., Geertsen, P. F., Fode, K. & Maase, H. V. D., 2006, I : Syopa. 106, s. 1130-1139 10 s.

Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma

Schmidt, H., Johansen, J. S., Sjoegren, P., Christensen, I. B., Sørensen, B. S., Fode, K., Larsen, J. & Maase, H. V. D., 2006, I : J. Clin. Oncol.. 24, s. 798-804 7 s.

Tumour-associated macrophages are related to progression in patients with      metastatic melanoma following interleukin-2 based immunotherapy

Hansen, B. D., Schmidt, H., Maase, H. V. D., Sjøgren, P. & Hokland, M., 2006, I : Acta. Oncol.. 45, s. 400-405 6 s.

Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy

Schmidt, H., Sorensen, B. S., Fode, K., Nexo, E. & von der Maase, H., 1 okt. 2005, I : Melanoma Research. 15, 5, s. 409-16 8 s.

A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma

Safwat, A., Schmidt, H., Bastholt, L., Fode, K., Larsen, S., Aggerholm, N. & Maase, H. V. D., 2005, I : Radiother. Oncol.. 77, 2, s. 143-147

Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model

Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I. J., Gehl, J. & Maase, H. V. D., 2005, I :   Br. J. Cancer. 93, s. 273-278 6 s.

The influence of immunohistochemistry on mRNA recovery from micro dissedted frozen and formalin-fixed, paraffin-embedded sections

Gjerdrum, L. M., Abrahamsen, H. N., Villegas, B., Sørensen, B. S., Schmidt, H. & Hamilton-Dutoit, S. J., dec. 2004, I : Diagnostic Molecular Pathology. 13, 4, s. 224-233 10 s.

S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma

Schmidt, H., Sørensen, B. S., Nexø, E. & Maase, H. V. D., jun. 2004, I : Melanoma Research. 14, 3, s. 211-15 5 s.

S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma

Schmidt, H., Sørensen, B. S., Nexø, E. & von der Maase, H., 2004, I : Melanoma Research. 14, 3, s. 211-5 4 s.

A phase II study of outpatients subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alfa in patients with metastatic melanoma

Schmidt, H., Larsen, S., Bastholt, L., Fode, K., Rytter, C. & Maase, H. V. D., dec. 2002, I : Annals of Oncology. 13, 12, s. 1919-1924 6 s.

Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma

Schmidt, H., Sørensen, H., Maase, H. V. D., Bang, C., Agger, R., Hokland, M. & Nexø, E., dec. 2002, I : Melanoma Research. 12, 6, s. 585-592 8 s.

Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study

Schmidt, H., Geertsen, P. F., Fode, K., Rytter, C., Bastholt, L. & von der Maase, H., 1 feb. 2000, I : Melanoma Research. 10, 1, s. 66-77 12 s.

Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR

Sørensen, B. S., Schmidt, H., von der Maase, H., Straten, P. T. & Nexø, E., 2000, I : Clinical Chemistry. 46, 12, s. 1923-8 5 s.